U
SRNE

UBS’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

UBS’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$4K Sell
996
-55
-5% -$295 ﹤0.01% 9665
2014
Q2 		$7K Sell
1,051
-34,807
-97% -$262K ﹤0.01% 9266
2014
Q1 		$460K Buy
35,858
+34,936
+3,789% +$387K ﹤0.01% 4319
2013
Q4 		$7K Buy
+922
New +$8.11K ﹤0.01% 9355

Other funds holding SRNE

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
B
Baird Milwaukee, Wisconsin $9.78B AUM 11.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

UBS's SRNE Position: Q3 2014 in Review

UBS reduced its Sorrento Therapeutics, Inc. (SRNE) stake by 5.2% in Q3 2014, selling an estimated $295 and leaving 996 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #9665.

UBS first reported a position in SRNE in Q4 2013 and has held it in 4 quarters since. The position peaked at $460K in Q1 2014. 33 funds tracked by Wall St. Rank hold SRNE as of Q3 2014.

  • UBS held 996 shares of Sorrento Therapeutics, Inc. worth $4K as of Q3 2014.
  • UBS sold 55 Sorrento Therapeutics, Inc. shares in Q3 2014, an estimated $295.
  • Sorrento Therapeutics, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9665 holding.
  • UBS first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and has held it in 4 quarters since.
  • UBS's Sorrento Therapeutics, Inc. position peaked at $460K in Q1 2014.
  • 33 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.